Michael Gibney
Senior Editor & Writer | LinkedInMichael Gibney is a senior writer and editor for PharmaVoice. Before that, he covered the pharmaceutical industry as a healthcare reporter for three and a half years at S&P Global Market Intelligence and served as an editor at FiercePharma and FierceBiotech. Besides industry reporting, Michael has also covered science, wildlife and environmental issues as well as local news in Connecticut and Montana. A graduate of Bucknell University and the University of Missouri Journalism School, he is based in the Washington, D.C., area where you’ll find him hiking with two retired racing greyhounds, finding local breweries and grilling in the backyard.
177 articles by Michael Gibney
-
Lilly’s adcomm win shows amyloid and tau will likely dominate Alzheimer’s — for now
June 13, 2024 -
As Big Pharma places bigger bets on ADCs, here’s where the field is headed next
June 11, 2024 -
A ‘widening gap’ in access to new cancer meds drives efforts from City of Hope and Bristol Myers
June 6, 2024 -
Merck and Moderna’s cancer vaccine snags a clinical win in a field decades old
June 3, 2024 -
As Senate’s gaze lands on patents, a former US PTO chief calls the effort a ‘broad misunderstanding’
May 30, 2024 -
Can robots break the cell therapy bottleneck?
May 29, 2024 -
AstraZeneca’s $80B sales goal by 2030 reflects industry’s penchant for long-term bets
May 23, 2024 -
Drug shortages, cost concerns and iffy access — how DTC and telehealth could even the playing field
May 22, 2024 -
Big Pharma leaders juggle pricing and access as IRA and supply constraints loom large
May 16, 2024 -
Big Pharma’s most improved drugs: a new generation of blockbusters
May 14, 2024 -
Lilly’s donanemab will face an Alzheimer’s adcomm in June, setting the stage for a Leqembi showdown
May 9, 2024 -
AZ oncology chief says AI can help solve cancer’s ‘ZIP code lottery’ as health disparities persist
May 8, 2024 -
$4M+ gene therapies? How payers can adapt to a new reality of pricey ‘cures’
May 2, 2024 -
Now a biopharma powerhouse, Vertex’s R&D bedrock could deliver tomorrow’s blockbusters
April 30, 2024 -
As Lilly and BMS invest in manufacturing, demand for drugs still outweighs supply
April 25, 2024 -
How pharma’s surging M&A is impacting the industry’s tech sector
April 11, 2024 -
Biosimilar uptake appears to finally be on the upswing, and Biocon Biologics is betting on the sector’s future
April 9, 2024 -
With an ovarian KRAS combo ready for review, Verastem’s CEO is poised for the transition
April 4, 2024 -
A dementia-focused VC digs past anti-amyloid for neuroscience diamonds in the rough
April 2, 2024 -
‘The heart is back,’ says Cardior CEO — Novo’s $1B+ deal rejuvenates a stale field
March 28, 2024 -
Alnylam turns to genealogy to find rare disease patients through family trees
March 26, 2024 -
An ocean of answers in a single cell — how proteomics can lead to better drugs
March 21, 2024 -
As investors ‘lose trust’ in pharma’s business model, focused M&A strategies can help
March 19, 2024 -
Former U.S. patent head on why federal march-in rights for drugs would be a ‘devastating’ mistake
March 14, 2024 -
The silver lining around Lilly’s Alzheimer’s delay could be a future with better drugs
March 12, 2024